BridgeBio Pharma Reports Month 12 Topline Results from Phase 3 ATTRibute-CM Study
– ATTRibute-CM did not meet its primary endpoint at Month 12. Mean observed six-minute walk distance (6MWD) decline for the acoramidis and placebo arms were 9 meters and 7 meters, respectively. Both declines are similar to healthy elderly adults and less than prior untreated ATTR-CM cohorts – The company observed improvements at Month 12 on […]